GlassScriptPhysician profile
Arveny Negron
NPI 1528477254
$953.15
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $55.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.82 | 2021 | |
| Lilly USA, LLC | $172.86 | 2021 | |
| Pfizer INC. | $68.38 | 2021 | |
| Abbvie INC. | $65.93 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $54.33 | 2021 | |
| Baxter Healthcare | $38.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.19 | 2021 | |
| Amgen INC. | $29.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.76 | 2021 | |
| Nevro Corp. | $23.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.95 | 2021 | |
| Astellas Pharma US INC | $22.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.16 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $17.87 | 2021 | |
| Genentech USA, INC. | $17.18 | 2021 | |
| Merck Sharp & Dohme LLC | $16.46 | 2021 | |
| Glaxosmithkline, LLC. | $15.88 | 2021 | |
| Abbott Laboratories | $14.90 | 2022 | |
| Nabriva Therapeutics, Plc | $13.43 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arveny Negron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.